Lupin Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Mr. Anand Kripalu as Independent Director. The pharmaceutical company's Board of Directors had previously approved his appointment as Additional Director (Non-Executive, Independent) effective February 01, 2026, during their meeting held on January 06, 2026.

Postal Ballot Notice Details

The company issued the postal ballot notice on January 14, 2026, to stock exchanges BSE Limited and National Stock Exchange of India Limited. The notice outlines the voting process and timeline for shareholder approval:

Board Appointment Framework

Mr. Kripalu's appointment was made based on the recommendation of the Nomination and Remuneration Committee. The appointment details include:

Professional Background and Expertise

Mr. Anand Kripalu brings over three decades of extensive industry experience in the fast-moving consumer goods sector. His distinguished career includes:

• Current Role: Executive Director of EPL Limited (previously Managing Director and Global CEO until December 31, 2025)
• Previous Leadership Positions: MD & CEO of Diageo India, President of India and South-East Asia at Mondelez International (Cadbury)
• Early Career: More than 20 years at Unilever in various general management, sales and marketing roles

Educational Qualifications and Current Directorships

Mr. Kripalu holds an MBA from IIM, Calcutta, and B. Tech (Electronics) from IIT Madras. He has completed the Advanced Management Program from Wharton Business School and received Distinguished Alumnus Awards from both IIM and IIT.

He currently serves as Independent Director at:

• Swiggy Limited
• United Breweries Limited
• PGP Glass Private Limited

Voting Process and Compliance

The postal ballot will be conducted exclusively through remote e-voting facility provided by NSDL. Members whose names appear in the Register of Members as on the cut-off date of January 09, 2026, are eligible to vote. The company has appointed Mr. Saurabh Agarwal or Ms. Deepti Kulkarni from M/s. Makarand M. Joshi & Co., Practicing Company Secretaries, as Scrutinizers for the voting process.

Lupin Limited confirmed that Mr. Kripalu is not debarred from holding the office of Director by SEBI or any other authority and is not related to any Directors, Key Managerial Personnel, or Promoters of the Company.

Lupin Ltd. has secured exclusive rights to commercialize and distribute Bofanglutide, a fortnightly injectable GLP-1 drug for diabetes and obesity management, in India through a strategic licensing agreement with China-based Gan & Lee Pharmaceuticals. The partnership positions the pharmaceutical company to expand its presence in the diabetes and obesity management segments with an innovative drug offering.

Strategic Partnership Details

The exclusive licensing, supply and distribution agreement grants Lupin comprehensive rights for the Indian market. The collaboration focuses on Bofanglutide, a fortnightly injectable GLP-1 drug that represents a significant advancement in diabetes and obesity treatment protocols.

Drug Characteristics and Competitive Advantages

Bofanglutide is positioned as potentially first-in-class globally, with clinical data demonstrating weight loss efficacy comparable to or better than existing GLP-1 therapies. The drug's primary differentiator lies in its dosing frequency, requiring administration only once every two weeks compared to the weekly injections required for current GLP-1 treatments.

The reduced dosing frequency addresses a significant patient compliance challenge in diabetes and obesity management. This convenience factor could enhance treatment adherence and improve patient outcomes in the Indian market.

Portfolio Impact and Market Position

This agreement strategically strengthens Lupin's diabetes treatment drug portfolio while simultaneously accelerating its entry into the obesity treatment segment. The partnership aligns with the growing demand for innovative diabetes management solutions and the emerging focus on obesity as a critical health concern.

The exclusive rights for India provide Lupin with a competitive advantage in a large and growing market for diabetes and obesity treatments.

Analyst Coverage and Stock Performance

Lupin maintains strong analyst coverage with 40 analysts tracking the stock. The analyst sentiment reflects cautious optimism about the company's prospects.

The stock closed the previous session at ₹2,082.00 per share, declining 1.40% during the trading session. Year-to-date performance shows the stock has declined 11.90%, reflecting broader market challenges and sector-specific factors affecting pharmaceutical companies.